VINCRISTINE SULFATE THERAPY IN CHILDREN WITH METASTATIC SOFT TISSUE SARCOMA

PEDIATRICS ◽  
1966 ◽  
Vol 38 (3) ◽  
pp. 465-472
Author(s):  
W. W. Sutow ◽  
D. H. Berry ◽  
T. B. Haddy ◽  
M. P. Sullivan ◽  
W. L. Watkins ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Actinomycin D ◽  
Drug Dosage ◽  
Cooperative Study ◽  
Vincristine Sulfate ◽  
Partial Control ◽  
Metastatic Soft Tissue Sarcoma ◽  
Trade Names

Sixteen children with metastatic or recurrent lesions from soft tissue sarcoma, mostly rhabdomyosarcoma, were treated with vincristine sulfate in a protocol-controlled cooperative study. Complete, though not permanent, regression of tumor occurred in two patients. Significant partial control of disease was achieved in three other children. Gastrointestinal or neurologic side-effects resulted in alteration of drug dosage schedule in 4 of 15 patients. The degree of antitumor activity in several of these cases was such that the further study of the effectiveness of the drug, particularly in combination with surgical and radiation therapy, in children with soft tissue sarcoma seems indicated. Generic and trade names of drugs: vincristine sulfate—Oncovin; cyclophosphamide—Cytoxan; chlorambucil—Leukeran; dactinomycin—Actinomycin-D.

scholarly journals The IVADo regimen?A pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma

Cancer ◽  
2005 ◽  
Vol 103 (8) ◽  
pp. 1719-1724 ◽  
Author(s):  
Gianni Bisogno ◽  
Andrea Ferrari ◽  
Christophe Bergeron ◽  
Angela Scagnellato ◽  
Arcangelo Prete ◽  
...  
Keyword(s):  
Pilot Study ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Actinomycin D ◽  
Metastatic Soft Tissue Sarcoma

scholarly journals Radiation Therapy in Metastatic Soft Tissue Sarcoma: From Palliation to Ablation

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4775
Author(s):  
Nishant K. Shah ◽  
Nikhil Yegya-Raman ◽  
Joshua A. Jones ◽  
Jacob E. Shabason
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Metastatic Disease ◽  
Local Control ◽  
Metastatic Cancer ◽  
Local Therapy ◽  
Primary Site ◽  
Metastatic Soft Tissue Sarcoma ◽  
Low Volume

The management of patients with metastatic cancer is rapidly changing. Historically, radiotherapy was utilized for the treatment of localized disease or for palliation. While systemic therapy remains the mainstay of management for patients with metastatic cancer, radiotherapy is becoming increasingly important not only to palliate symptoms, but also to ablate oligometastatic or oligoprogressive disease and improve local control in the primary site. There is emerging evidence in multiple solid malignancies that patients with low volume metastatic disease that undergo local ablative therapy to metastatic sites may have improved progression free survival and potentially overall survival. In addition, there is increasing evidence that select patients with metastatic disease may benefit from aggressive treatment of the primary site. Patients with metastatic soft tissue sarcoma have a poor overall prognosis. However, there may be opportunities in patients with low volume metastatic soft tissue sarcoma to improve outcomes with local therapy including surgery, ablation, embolization, and radiation therapy. Stereotactic body radiation therapy (SBRT) offers a safe, convenient, precise, and non-invasive option for ablation of sites of metastases. In this review article, we explore the limited yet evolving role of radiotherapy to metastatic and primary sites for local control and palliation, particularly in the oligometastatic setting.

The Evolving Role of Radiation Therapy in Patients with Metastatic Soft Tissue Sarcoma

2020 ◽  
Vol 22 (8) ◽  
Author(s):  
Ahsan Farooqi ◽  
Devarati Mitra ◽  
B. Ashleigh Guadagnolo ◽  
Andrew J. Bishop
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Metastatic Soft Tissue Sarcoma

Non-surgical Treatments for Lung Metastases in Patients with soft Tissue Sarcoma: Stereotactic Body Radiation Therapy (SBRT) and Radiofrequency Ablation (RFA)

2020 ◽  
Vol 16 ◽  
Author(s):  
Cecilia Tetta ◽  
Maria Carpenzano ◽  
Areej Tawfiq J Algargoush ◽  
Marwah Algargoosh ◽  
Francesco Londero ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Stereotactic Body Radiation Therapy ◽  
Lung Metastases ◽  
Disease Free Interval ◽  
Stereotactic Body Radiation ◽  
Free Interval ◽  
Disease Free

Background: Radio-frequency ablation (RFA) and Stereotactic Body Radiation Therapy (SBRT) are two emerging therapies for lung metastases. Introduction: We performed a literature review to evaluate outcomes and complications of these procedures in patients with lung metastases from soft tissue sarcoma (STS). Method: After selection, seven studies were included for each treatment encompassing a total of 424 patients: 218 in the SBRT group and 206 in the RFA group. Results: The mean age ranged from 47.9 to 64 years in the SBRT group and from 48 to 62.7 years in the RFA group. The most common histologic subtype was, in both groups, leiomyosarcoma. : In the SBRT group, median overall survival ranged from 25.2 to 69 months and median disease-free interval from 8.4 to 45 months. Two out of seven studies reported G3 and one G3 toxicity, respectively. In RFA patients, overall survival ranged from 15 to 50 months. The most frequent complication was pneumothorax. : Local control showed high percentage for both procedures. Conclusion: SBRT is recommended in patients unsuitable to surgery, in synchronous bilateral pulmonary metastases, in case of deep lesions and in patients receiving high-risk systemic therapies. RFA is indicated in case of a long disease-free interval, in oligometastatic disease, when only the lung is involved, in small size lesions far from large vessels. : Further large randomized studies are necessary to establish whether these treatments may also represent a reliable alternative to surgery.

Sign in / Sign up

Export Citation Format

Share Document